Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Visit

SOHO 2022 | Dose modification of ponatinib in CP-CML: data from the PACE and OPTIC trials

Elias Jabbour • 28 Sep 2022

SOHO 2022

Chronic Myeloid Leukemia Leukemia Ponatinib

OPTIC PACE

Elias Jabbour, MD, University of Texas MD Anderson Cancer Center, Houston, TX, discusses the feasibility of modifying the dose of ponatinib in patients with chronic-phase chronic myeloid leukemia (CP-CML) to decrease the incidence of vascular events, highlighting data from the PACE (NCT01207440) and OPTIC (NCT02467270) trials. Overall, it was shown that adjusting drug dose based on response optimized treatment safety without compromising efficacy. This interview took place at the Tenth Annual Meeting of the Society of Hematologic Oncology (SOHO) held in Houston, TX.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Updated results of hyper-CVAD and blinatumomab +/- inotuzumab ozogamicin in newly-diagnosed B-ALL

Elias Jabbour • 10 Dec 2023

Obe-cel for R/R B-ALL: pooled analysis of the ongoing FELIX study

Elias Jabbour • 10 Dec 2023

An update on olverembatinib in patients with R/R CML and Ph+ ALL

Elias Jabbour • 10 Dec 2023

Phase I trial of the menin inhibitor JNJ-75276617 in patients with acute leukemia

Elias Jabbour • 10 Dec 2023

Related Videos

Comparing the efficacy of salvage therapies in adult B-ALL: a retrospective real-world study

Alex Rampotas • 16 Apr 2024

Total marrow and lymphoid irradiation plus cyclophosphamide & etoposide in poor-risk acute leukemias

Anthony Stein • 15 Apr 2024

Manipulating the gut microbiome to improve outcomes of alloSCT for hematological malignancies

Florent Malard • 11 Apr 2024

Investigating mutation order in AML using single-cell sequencing

Ravindra Majeti • 8 Apr 2024